About this Guide
This guide provides supplementary clinical context for the Entyvio Dosing Calculator. It details the tool’s inputs, outputs, and the standard dosing principles for vedolizumab in adult patients with Ulcerative Colitis (UC) and Crohn’s Disease (CD), based on the FDA-approved prescribing information.
Outputs
After entering the required patient information, the calculator provides a clear summary of the recommended dosing protocol, including:
- Recommended Dose: The specific milligram (mg) dose for the selected phase (e.g., 300 mg for IV, 108 mg for SC).
- Route of Administration: Specifies whether the dose is Intravenous (IV) infusion or Subcutaneous (SC) injection.
- Dosing Frequency: The standard interval between doses (e.g., Week 0, 2, 6 for induction; every 8 weeks for IV maintenance).
- Projected Schedule: If a start date is provided, the tool generates a list of projected dates for the next 3-4 administrations to aid in treatment planning.
How to Use
To use the calculator, follow these steps:
- Enter Patient Weight: Input the patient’s weight and select the appropriate unit (kg or lbs). The tool automatically converts lbs to kg for documentation.
- Select Indication: Choose either Ulcerative Colitis (UC) or Crohn’s Disease (CD).
- Choose Dosing Phase / Formulation: Select the relevant treatment phase: IV Induction, IV Maintenance, or SC Maintenance.
- Add Start Date (Optional): Enter the treatment initiation date to generate a projected dosing schedule. This is particularly useful for visualizing the induction and maintenance timelines.
Dosing Overview
Vedolizumab dosing is standardized for adults and is not weight-based. The protocol is divided into an initial IV induction phase followed by a maintenance phase, which can be either IV or SC.
Induction Phase (IV)
All patients begin treatment with intravenous induction therapy, regardless of indication.
- Dose: 300 mg IV infusion
- Schedule: Administered at Week 0, Week 2, and Week 6.
- Administration: Infused over approximately 30 minutes. Patients should be monitored during and after infusion.
Maintenance Phase (IV)
Following the induction phase, patients can continue with IV maintenance therapy.
- Dose: 300 mg IV infusion
- Schedule: Administered every 8 weeks, starting at Week 14.
Maintenance Phase (SC)
As an alternative to IV maintenance, patients may switch to subcutaneous injections after completing at least two induction IV infusions.
- Dose: 108 mg SC injection
- Schedule: Administered every 2 weeks.
Switching
Patients may transition from IV to SC maintenance therapy. The first SC dose should be administered at the time of the next scheduled IV infusion. The calculator assumes patients have completed the required IV induction phase before starting SC maintenance.
Missed Dose
If a dose of Entyvio is missed, the patient should be advised to receive it as soon as possible. The subsequent dosing schedule should be adjusted accordingly to maintain the correct interval between doses. Clinical judgment should be used to manage the patient’s schedule.
Safety Alerts
Vedolizumab is associated with potential risks. Key safety considerations include:
- Infections: Entyvio may increase the risk of infections. Patients should be monitored for signs and symptoms of infection during treatment.
- Infusion-Related Reactions (IRRs) and Hypersensitivity: Reactions such as anaphylaxis, dyspnea, bronchospasm, and rash can occur. Appropriate monitoring and medical support should be available during IV administration.
- Progressive Multifocal Leukoencephalopathy (PML): Although no cases have been reported with Entyvio, a risk of this rare and serious brain infection exists with some integrin receptor antagonists.
Frequently Asked Questions (FAQ)
How is patient weight used in the calculation?
Patient weight is recorded for clinical context and documentation. The Entyvio dose for adults (300 mg IV or 108 mg SC) is a fixed dose and is not adjusted based on patient weight.
Does the calculator support pediatric dosing?
No, this calculator is designed for adult dosing regimens only as described in the standard FDA label. Pediatric dosing may differ and requires consultation with specialized guidelines.
Can a patient start directly with SC maintenance therapy?
No. According to the prescribing information, patients must first undergo IV induction (at least two doses at Week 0 and Week 2) to ensure an adequate therapeutic response before starting SC maintenance.
What happens if I enter a weight in pounds (lbs)?
The tool automatically converts the weight from lbs to kilograms (kg) using the standard conversion factor (1 lb ≈ 0.453592 kg) and displays the kg value in the output for accurate record-keeping.
Why is the start date optional?
The core function of the calculator is to determine the correct dose and frequency. The start date is an optional feature that enhances the tool by generating a convenient, projected schedule of future dose dates.
Does the calculator account for dose adjustments due to inadequate response?
No, the calculator only provides the standard, approved dosing schedule. Any decisions to adjust therapy, such as increasing IV maintenance frequency, must be based on individual clinical assessment.
Is the Subcutaneous (SC) dose of 108 mg equivalent to the 300 mg IV dose?
The 108 mg SC dose every 2 weeks is designed to maintain vedolizumab trough concentrations comparable to those achieved with the 300 mg IV dose every 8 weeks, demonstrating similar efficacy in maintenance therapy.
Where does the calculator source its dosing information?
All dosing logic is based on the official FDA-approved Prescribing Information for Entyvio (vedolizumab). The tool’s logic was last updated relative to the information available in September 2023.
References
- ENTYVIO® (vedolizumab) Prescribing Information. U.S. Food and Drug Administration. Takeda Pharmaceuticals America, Inc.
- Entyvio (vedolizumab) Dosing & Administration. Takeda Pharmaceuticals. HCP Website.
- Entyvio (vedolizumab) Summary of Product Characteristics (SmPC). European Medicines Agency.
- Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710. doi:10.1056/NEJMoa1215734
